Method for enhancing cognition using ziprasidone

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/496 (2006.01) A61P 25/18 (2006.01)

Patent

CA 2525323

The present invention, in one aspect, relates to a method of using piperazinyl- heterocyclic compounds of the formula (I), as defined below, for enhancing cognition in a mammal, including a human, for example a mammal afflicted with psychosis, autism, dementia, or mental retardation, comprising administering an effective amount of a compound of formula (I) (for example, ziprasidone) to the mammal. In another aspect, the present invention is directed to a method for reducing or ameliorating in a mammal, including a human, afflicted with a disorder or condition selected from autism, mental retardation, obsessive- compulsive disorder, and dementia, positive symptoms (e.g. excessive aggression, disinhibited sexual behavior, inappropriate sexual behavior, agitation, compulsive behavior such as head banging, lip bighting, self mutilation, or stereotypic behavior) associated with the aforementioned disorders or conditions, which method comprises administering an effective amount of a compound of formula (I) (for example, ziprasidone) to the mammal. In another aspect, the present invention is directed to a method for treating pediatric bipolar disorder in a mammal, including a human, which method comprises administering an effective amount of a compound of formula (I) (for example, ziprasidone) to the mammal. The compounds of compound of the formula (I) are defined as follows: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

Un aspect de l'invention porte sur l'utilisation de composés hétérocycliques de piperazinyle de la formule (I), comme définie ci-dessous, pour améliorer les fonctions cognitives chez un mammifère, dont l'homme, par exemple chez un mammifère souffrant de psychose, d'autisme, de démence, ou de déficiences mentales. Le procédé consiste à administrer une dose efficace d'un composé de la formule (I) (par exemple, le ziprasidone) au mammifère. Un autre aspect de l'invention porte sur un procédé permettant de réduire ou de soulager chez un mammifère, notamment chez l'homme, les symptômes associés à des troubles ou des pathologies telles que l'autisme, la déficience mentale, le trouble obsessif-compulsif, la démence, les symptômes positifs (par exemple, le comportement agressif excessif, le comportement sexuel incontrôlé, le comportement sexuel inapproprié, l'agitation, le comportement compulsionnel tel que se cogner la tête, se mordre les lèvres, l'automutilation ou le comportement stéréotype) associés aux troubles ou aux pathologies mentionnés ci-dessus. Le procédé consiste à administrer une dose efficace d'un composé de la formule (I) (par exemple, le ziprasidone) au mammifère. Un autre aspect de l'invention porte sur un procédé permettant de traiter des troubles bipolaires pédiatriques chez un mammifère, dont l'homme, qui consiste à administrer une dose efficace d'un composé de la formule (I) (par exemple, le ziprasidone) au mammifère. Les composés du composé de la formule (I) sont définis selon la formule: ou un de ses sels d'addition acide acceptables sur le plan pharmaceutique, dans laquelle Ar, n, X, et Y sont tels que définis.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Method for enhancing cognition using ziprasidone does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for enhancing cognition using ziprasidone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhancing cognition using ziprasidone will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1549795

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.